Version history

{
  "session_id": "sess_SDA-2026-04-16-gap-debate-20260410-113045-27c7b314_20260421-011124",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Pulsed TRPML1 Windowing Restores Flux\",\n      \"mechanism\": \"Low-dose, time-limited TRPML1 activation produces lysosomal Ca2+ microdomains that activate calcineurin-TFEB and fusion without depleting lysosomal Ca2+ reserve.\",\n      \"target_gene\": \"MCOLN1\",\n      \"confidence_score\": 0.66,\n      \"novelty_score\": 0.72,\n      \"feasibility_score\": 0.62,\n      \"impact_score\": 0.76,\n      \"composite_score\": 0.70,\n      \"testable_prediction\": \"A pulsed ML-SA1-like regimen will improve LC3 flux, p62 clearance, TFEB nuclear localization, and neuronal survival while preserving lysosomal Ca2+ and avoiding galectin-3 puncta.\",\n      \"skeptic_concern\": \"The same TFEB/fusion signal may become toxic if aged lysosomes cannot replenish Ca2+ or maintain pH.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Autophagy Priming Widens TRPML1 Safety Margin\",\n      \"mechanism\": \"Autophagy priming increases lysosomal demand and biogenesis capacity before TRPML1 agonism, converting channel activation from a depletion stress into a productive fusion and replenishment signal.\",\n      \"target_gene\": \"MCOLN1; ATG7; TFEB\",\n      \"confidence_score\": 0.60,\n      \"novelty_score\": 0.70,\n      \"feasibility_score\": 0.58,\n      \"impact_score\": 0.72,\n      \"composite_score\": 0.66,\n      \"testable_prediction\": \"Delayed autophagy priming followed by TRPML1 agonism will outperform simultaneous dosing and monotherapy in human neuron models with bafilomycin-controlled flux assays.\",\n      \"skeptic_concern\": \"Rapamycin and related primers have broad mTOR and metabolic effects, so synergy must be shown to be MCOLN1-dependent.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Mitophagy Context Determines TRPML1 Benefit\",\n      \"mechanism\": \"TRPML1 activation is beneficial when PINK1/Parkin mitophagy can deliver damaged mitochondria to lysosomes, but becomes less effective or harmful when mitochondrial quality-control input remains defective.\",\n      \"target_gene\": \"MCOLN1; PINK1; PARK2; LRRK2\",\n      \"confidence_score\": 0.56,\n      \"novelty_score\": 0.76,\n      \"feasibility_score\": 0.54,\n      \"impact_score\": 0.70,\n      \"composite_score\": 0.64,\n      \"testable_prediction\": \"TRPML1 agonism will show a wider therapeutic index in PINK1/Parkin-competent neurons than in PINK1/PARK2 loss-of-function or LRRK2-G2019S neurons unless combined with mitochondrial stress reduction.\",\n      \"skeptic_concern\": \"The interaction direction may invert by genotype, disease stage, and glial context.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"TRPML1 is a plausible lysosomal target but should be developed as a windowed signalling intervention, not a simple chronic activator.\",\n    \"The decisive measurements are complete autophagic flux, lysosomal Ca2+ reserve, lysosomal membrane integrity, and neuronal survival.\",\n    \"Patient or model stratification by lysosomal and mitochondrial quality-control state is essential.\"\n  ],\n  \"dissent_points\": [\n    \"Theorist expects sequential priming to widen the window, while Skeptic argues rapamycin confounding and aged-lysosome fragility may erase the advantage.\",\n    \"The PINK1/Parkin interaction could define either a responsive subgroup or a subgroup where TRPML1 stimulation is insufficient.\"\n  ],\n  \"debate_summary\": \"The debate supports TRPML1 enhancement as scientifically valuable but only under a tightly measured exposure window. The strongest path is pulsed or sequential activation with explicit safety biomarkers for Ca2+ depletion, lysosomal membrane permeabilization, and failed flux.\"\n}",
  "tokens_used": "895"
}